New drug CS-1103 tested as potential fentanyl overdose treatment
NCT ID NCT07459166
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This Phase 2 trial tests a single dose of CS-1103 in 16 healthy adults who also receive fentanyl (a strong opioid) and naloxone (an overdose reversal drug). The goal is to see if CS-1103 is safe and how it affects fentanyl levels in the body. It is an early study to gather safety data, not yet testing in real overdose situations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CS-1103
- What this could lead to
- If successful, this could point toward a new treatment for fentanyl overdose, potentially offering an alternative to naloxone.
- What could go wrong
- This is a very early, small Phase 2 trial in healthy volunteers, not real overdose patients. It may not work in actual emergencies or have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FENTANYL OVERDOSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
California Clinical Trials Medical Group
RECRUITINGGlendale, California, 91206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.